|
1
|
Lo-Coco F, Cimino G, Breccia M, Noguera
NI, Diverio D, Finolezzi E, Pogliani EM, Di Bona E, Micalizzi C,
Kropp M, et al: Gemtuzumab ozogamicin (Mylotarg) as a single agent
for molecularly relapsed acute promyelocytic leukemia. Blood.
104:1995–1999. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Takeshita A, Shinjo K, Naito K, Matsui H,
Sahara N, Shigeno K, Horii T, Shirai N, Maekawa M, Ohnishi K, et
al: Efficacy of gemtuzumab ozogamicin on ATRA- and
arsenic-resistant acute promyelocytic leukemia (APL) cells.
Leukemia. 19:1306–1311. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aribi A, Kantarjian HM, Estey EH, Koller
CA, Thomas DA, Kornblau SM, Faderl SH, Laddie NM, Garcia-Manero G
and Cortes JE: Combination therapy with arsenic trioxide, all-trans
retinoic acid, and gemtuzumab ozogamicin in recurrent acute
promyelocytic leukemia. Cancer. 109:1355–1359. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sanz MA, Montesinos P, Rayón C, Holowiecka
A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera
JM, et al: Risk-adapted treatment of acute promyelocytic leukemia
based on all-trans retinoic acid and anthracycline with addition of
cytarabine in consolidation therapy for high-risk patients: Further
improvements in treatment outcome. Blood. 115:5137–5146. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ravandi F, Estey E, Jones D, Faderl S,
O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W,
et al: Effective treatment of acute promyelocytic leukemia with
all-trans-retinoic acid, arsenic trioxide and gemtuzumab
ozogamicin. J Clin Oncol. 27:504–510. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ravandi F, Estey EH, Appelbaum FR, Lo-Coco
F, Schiffer CA, Larson RA, Burnett AK and Kantarjian HM: Gemtuzumab
ozogamicin: Time to resurrect? J Clin Oncol. 30:3921–3923. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lo-Coco F, Latagliata R and Breccia M:
Management of acute promyelocytic leukemia in the elderly. Mediterr
J Hematol Infect Dis. 5:e20130452013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takeshita A: Efficacy and resistance of
gemtuzumab ozogamicin for acute myeloid leukemia. Int J Hematol.
97:703–716. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takeshita A, Shinjo K, Naito K, Matsui H,
Sahara N, Shigeno K, Suzumura T, Horii T, Shirai N, Maekawa M, et
al: Two patients with all-trans retinoic acid-resistant acute
promyelocytic leukemia treated successfully with gemtuzumab
ozogamicin as a single agent. Int J Hematol. 82:445–448. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sanz MA, Martín G, González M, León A,
Rayón C, Rivas C, Colomer D, Amutio E, Capote FJ, Milone GA, et al:
Risk-adapted treatment of acute promyelocytic leukemia with
all-trans-retinoic acid and anthracycline monochemotherapy: A
multicenter study by the PETHEMA group. Blood. 103:1237–1243. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Petersdorf SH, Kopecky KJ, Slovak M,
Willman C, Nevill T, Brandwein J, Larson RA, Erba HP, Stiff PJ,
Stuart RK, Walter RB, Tallman MS, Stenke L and Appelbaum FR: A
phase 3 study of gemtuzumab ozogamicin during induction and
postconsolidation therapy in younger patients with acute myeloid
leukemia. Blood. 121:4854–4860. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ikezoe T: Pathogenesis of disseminated
intravascular coagulation in patients with acute promyelocytic
leukemia, and its treatment using recombinant human soluble
thrombomodulin. Int J Hematol. 100:27–37. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ikezoe T, Takeuchi A, Isaka M, Arakawa Y,
Iwabu N, Kin T, Anabuki K, Sakai M, Taniguchi A, Togitani K and
Yokoyama A: Recombinant human soluble thrombomodulin safely and
effectively rescues acute promyelocytic leukemia patients from
disseminated intravascular coagulation. Leuk Res. 36:1398–1402.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kawano N, Kuriyama T, Yoshida S, Yamashita
K, Ochiai H, Nakazaki S, Tasaki A and Ueda A: Clinical features and
treatment outcomes of six patients with disseminated intravascular
coagulation resulting from acute promyelocytic leukemia and treated
with recombinant human soluble thrombomodulin at a single
institution. Intern Med. 52:55–62. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shindo M, Ikuta K, Addo L, Ito S, Fujiya
M, Torimoto Y and Kohgo Y: Successful control of disseminated
intravascular coagulation by recombinant thrombomodulin during
arsenic trioxide treatment in relapsed patient with acute
promyelocytic leukemia. Case Rep Hematol.
2012:9081962012.PubMed/NCBI
|
|
16
|
Ikezoe T, Yang J, Nishioka C, Isaka M,
Iwabu N, Sakai M, Taniguchi A, Honda G and Yokoyama A:
Thrombomodulin enhances the antifibrinolytic and antileukemic
effects of all-trans retinoic acid in acute promyelocytic leukemia
cells. Exp Hematol. 40:457–465. 2012. View Article : Google Scholar : PubMed/NCBI
|
